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Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus
ondopaminergictherapies,includingL-dopaanddopaminereceptoragonists.However,thesetreatmentsinduceneuropsychiatric
side eﬀects. Psychosis, characterized by delusions and hallucinations, is one of the most serious such side eﬀects. Adenosine A2A re-
ceptor antagonism is a nondopaminergic treatment for PD with clinical and preclinical eﬃcacy. The present studies assessed A2A
antagonists SCH 412348 and istradefylline in rodent prepulse inhibition (PPI), a model of psychosis. Dopamine receptor agonists
pramipexole (0.3–3mg/kg), pergolide (0.3–3mg/kg), and apomorphine (0.3–3mg/kg) signiﬁcantly disrupted PPI; ropinirole (1–
30mg/kg) had no eﬀect; L-dopa (100–300mg/kg) disrupted rat but not mouse PPI. SCH 412348 (0.3–3mg/kg) did not disrupt
rodentPPI;istradefylline(0.1–1mg/kg)marginallydisruptedmousebutnotratPPI.TheseresultssuggestthatA2A antagonists,un-
like dopamine agonists, have an improved neuropsychiatric side eﬀect proﬁle.
1.Introduction
Parkinson’sdisease(PD)ischaracterizedbyaprogressiveloss
ofdopaminergicneuronsinthesubstantianigraregionofthe
basal ganglia, which results in movement-related symptoms.
Current treatment for PD includes dopamine replacement
therapyintheformofL-dopa,aprecursortodopamine(DA)
in its synthesis pathway that has been the gold standard of
carefordecades.Morerecently,DAreceptoragonists,suchas
pramipexole, pergolide, and ropinirole, have become more
commonly prescribed for the treatment of PD.
PD is primarily associated with motor symptoms, but
nonmotor neuropsychiatric symptoms have garnered recent
attention as serious complications that negatively impact
quality of life [1, 2]. Psychosis, mostly in the form of visual
hallucinations and sometimes paranoid delusions, is a trou-
bling neuropsychiatric symptom in PD patients. Treatment
with dopaminergic medication is a risk factor for develop-
ing psychosis. Up to 40% of PD patients treated with dop-
aminergic agents experience psychotic symptoms, of which
the most common manifestations are visual hallucinations
[3, 4], whereas less than 10% of untreated PD patients
experience psychotic symptoms [5]. Among the antiparkin-
sonian medications, studies have shown that DA receptor
agonists are more likely to induce psychoses than L-dopa [5–
7]. First-line treatment for psychosis in PD is typically dose
reduction of dopaminergic agents. Second-line treatment
is administration of atypical antipsychotics, particularly
clozapine and quetiapine [8]. However, these drugs carry
the risk of worsening the motor symptoms of PD either by
counteracting the dopaminergic treatment eﬀects or induc-
ing extrapyramidal side eﬀects [9]. Better treatment options
for PD without the associated psychosis liability would be
extremely beneﬁcial.
Given the clinical link between dopaminergic therapies
and psychoses, preclinical models of psychosis that are tran-
slatable to humans are necessary to predict the psychosis risk
of novel PD medications. Prepulse inhibition (PPI) of startle2 Parkinson’s Disease
is a preclinical model of sensory gating that we used in the
current studies to evaluate this risk for A2A receptor antago-
nists. Typically, PPI deﬁcits are associated with neuropsychi-
atric disorders such as schizophrenia. DA receptor agonists
disruptPPIinratsandhumans[10–12],whichdemonstrates
the cross-species reliability of the PPI model. These ﬁndings
also provide evidence that PPI disruptions can be used to
predict neuropsychiatric side eﬀects of PD medications.
Adenosine A2A receptor antagonism has recently emerg-
ed as a potential novel nondopaminergic treatment for PD.
A2A receptors are abundant in the GABAergic neurons of the
indirect pathway of the basal ganglia [13]. The location of
these receptors suggests that they are potent neuromodula-
tors and may regulate excitatory input to the striatum, which
is an important target for PD treatment due to its involve-
ment in the controlof voluntary movements [14].A2A recep-
tor antagonism has proven beneﬁcial in clinical trials. In a
recent phase II clinical trial, the A2A antagonist preladenant
was found to decrease oﬀ time and motor ﬂuctuations in pa-
tients with PD receiving L-dopa [15].
A2A receptor antagonists have also demonstrated eﬃcacy
in animal models of PD. The A2A receptor antagonist istra-
defylline (KW-6002) increased locomotor activity in MPTP-
treatedmiceanddecreasedmousecatalepsyinducedbyhalo-
peridolorreserpine[16].Ofparticularinteresttothepresent
studies is SCH 412348, which is a novel and potent A2A anta-
gonist that displays high selectivity (>1000-fold) over all
other adenosine receptor subtypes (Ki = 0.6nM) [17]. SCH
412348 (0.1–1.0mg/kg) has been shown to potentiate L-
dopa-induced rotations in 6-OHDA-lesioned rats and re-
verse rat haloperidol-induced catalepsy, two rodent models
predictive of antiparkinsonian eﬃcacy [17].
The purpose of the current research was to evaluate any
potential psychosis liability of A2A antagonists. SCH 412348
and istradefylline were assessed in both rat and mouse PPI
and compared to current dopamine-based PD therapies
(pra-mipexole, pergolide, ropinirole, L-dopa, and apomor-
phine).DosestestedinPPIwerebasedoneﬃcacyinrathalo-
peridol-induced catalepsy.
2.MaterialsandMethods
2.1. Animals. Male CD rats weighing 180–220g and 250–
450g were used in catalepsy and PPI studies, respectively.
Male C57BL/6 mice (20–25g) were used in mouse PPI stud-
ies.AnimalswerepurchasedfromCharlesRiverLaboratories
(Kingston, NY, USA). Animals were group-housed with food
and water available ad libitum. Studies were conducted dur-
ing the light phase of a 12h light/dark cycle under standard
laboratory conditions (constant temperature and humidity).
Animal care and testing procedures were conducted in con-
formity with the Merck Institutional Animal Care and Use
Committee, and in compliance with the “Guide for the Care
andUseofLaboratoryAnimals”(NationalResearchCouncil,
1996) and the Animal Welfare Act.
2.2. Drugs. Haloperidol, pergolide mesylate, ropinirole hyd-
rochloride, L-dopa, benserazide, and apomorphine were
obtained from Sigma-Aldrich (St. Louis, Mo, USA). Prami-
pexole·2HCl was purchased from Tecoland Corporation
(Edison, NJ, USA). For catalepsy studies, haloperidol was
preparedwithdistilledwaterandbroughttoapHof5-6with
0.1N HCl and 0.1M NaOH. A dose of 1mg/kg was admin-
istered SC 30min prior to catalepsy testing. SCH 412348
([7-[2-[4-2,4-diﬂuorophenyl]-1-piperazinyl]ethyl]-2-(2-fu-
ranyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-
5-amine) and istradefylline [(E)-8-(3,4-dimethoxystyryl)-
1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione]
were synthesized by the Department of Chemical Research at
Merck Research Laboratories. SCH 412348 was prepared in
0.4% methylcellulose and administered orally 60min prior
to behavioral testing. Istradefylline was dissolved in 5%
Tween 80 in saline and administered orally 60min prior to
behavioral testing. Pramipexole was dissolved in saline and
injected sc. 30min prior to behavioral testing. Pergolide was
prepared in saline and dosed ip. 10min prior to testing. Rop-
inirolewasdissolvedinsalineandinjectedip.60minpriorto
testing. L-dopa was prepared in saline and administered ip.
60min prior to catalepsy or PPI testing. Twenty min prior to
L-dopa, benserazide dissolved in saline was injected ip. (2:1
ratio of L-dopa to benserazide) to prevent peripheral decar-
boxylation of L-dopa. Apomorphine solution in 0.1% ascor-
bic acid was administered sc. 5min prior to PPI testing. In
rats, dose volume for oral administration was 5mL/kg, while
dosevolumeforbothsc.andip.administrationwas1mL/kg.
Dose volume for all routes of administration in mice was
10mL/kg.
2.3. Haloperidol-Induced Catalepsy Procedure. The catalepsy
procedure followed that described by Hodgson et al., in
2009 [17]. Catalepsy was measured using an angled wire
mesh screen (60◦ angle, 59cm (W) × 24cm (D) × 56.0cm
(H); mesh 5mm2). The duration of catalepsy was scored by
an experimenter using a hand-held timer. Rats were ﬁrst
injected with haloperidol to induce catalepsy. Thirty minutes
later, each rat was placed on the wire mesh screen with its
head facing upward and forelimbs and hindlimbs extended.
To prescreen the rats to ensure they were responsive to
haloperidol, they were given two trials to demonstrate
catalepsy (operationally deﬁned as remaining still without
lifting a paw from the wire mesh) for 120sec to meet study
inclusion threshold. Haloperidol was not injected a second
time for the second trial. Rats that met the criterion (roughly
85% of the rats tested) on at least one of the two trials were
injectedwiththedrugofinterestandtestedforcatalepsyafter
the appropriate pretreatment time. The latency to move a
pawwasthedependentmeasureinthecatalepsystudies,with
all trials truncated at 120sec. Studies were conducted using a
between-subjects design.
2.4. Prepulse Inhibition Procedure. Ventilated and lighted
startle chambers (SR-LAB; San Diego Instruments, San
Diego,Calif,USA)wereutilizedforallPPIexperiments.Each
chamber (33 × 33 × 46cm) was equipped with a loud-
speaker (acoustic source) and a Plexiglas cylindrical animal
enclosure (internal diameter: 8.8cm for rat, 3.8cm forParkinson’s Disease 3
mouse) mounted on a Plexiglas base. Startle responses were
transduced by a piezoelectric accelerometer mounted below
thecylinder.Theloudspeakerwaspositionedabovethecylin-
der and produced the mixed frequency stimuli (background
noise, prepulse and pulse stimuli).
Test sessions began with a 5min acclimation period, dur-
ing which a background noise was presented in the absence
of any startle stimuli. The animals were then subjected to
a series of acoustic startle trials. For mouse PPI, the animals
received six trial types: no stimulus, startle alone (130dB,
40ms), highest prepulse alone (20ms), and three diﬀerent
prepulses (5dB, 10dB, and 15dB, 20ms) preceding a startle
stimulus by 100ms. Each trial type was presented in a pseu-
dorandomorderwith12presentationsofeach,inadditionto
an initial single pulse alone trial which began the test session.
Thisinitialpulsetrialwasnotusedindataanalysis.Theinter-
trialintervalaveraged18s(10–25srange).ForratPPI,atotal
of 41 trials were presented. They consisted of ﬁve trial types:
no stimulus, startle alone (120dB, 40ms), and 3 prepulse
stimuli (5, 10, and 15dB above 65dB background, 20ms),
each preceding the startle stimulus by 100ms. Each trial type
was presented in a pseudorandom order with 8 presentations
of each in addition to an initial single pulse alone trial, which
was not used for data analysis. The average intertrial interval
was 20s (15–25s range). PPI data are expressed as an average
of the percent inhibition of startle produced by the 5, 10, and
15dB prepulse trials. Mean startle magnitude was calculated
based on the startle alone trials. All animals were initially
subjected to a baseline testing day without pharmacological
manipulationinordertocreategroupswithequivalentmean
baseline levels of startle and PPI. All studies were conducted
using a between-subjects design.
2.5. Statistical Analysis. All data are expressed as means ±
the standard error of the mean (SEM). All studies were anal-
yzed using one-way ANOVAs. Dunnett’s tests were used to
determineindividualdosegroupswithsigniﬁcantreductions
in time cataleptic compared to the haloperidol + vehicle
group for catalepsy studies or individual dose groups with
signiﬁcant reductions in percent PPI or startle compared to
the vehicle group in PPI studies. Signiﬁcance was deﬁned as
P<0.05.
3. Results
3.1. Haloperidol-Induced Catalepsy. Figure 1 shows treat-
ment eﬀects on rat haloperidol-induced catalepsy. The A2A
antagonists SCH 412348 (Figure 1(a)) and istradefylline
(Figure 1(b)) signiﬁcantly reversed rat haloperidol-induced
catalepsy (SCH 412348: F(5, 42) = 15.57, P<0.01; istra-
defylline: F(5, 42) = 9.20, P<0.01), with the 0.3, 1, and
3mg/kg groups and the 0.3 and 1mg/kg groups, respec-
tively, spending signiﬁcantly less time cataleptic than the
vehicle + haloperidol group. The DA receptor agonists pra-
mipexole, pergolide and ropinirole also reduced halo-
peridol-induced catalepsy in rats. Pramipexole eﬀects (F(6,
35) = 7.57, P<0.01) were signiﬁcantly diﬀerent from
vehicle at 0.1, 0.3, 1, and 3mg/kg (Figure 1(c)), while per-
golide (F(5, 42) = 19.98, P<0.01) showed signiﬁcant eﬀects
comparedtovehicleatdosesof3and10mg/kg(Figure 1(d)).
Ropinirole reduced time cataleptic (F(5, 30) = 11.42,
P<0.01) at 10mg/kg, whereas 1 and 3mg/kg showed
marginal signiﬁcance (P = 0.06) compared to vehicle +
haloperidol treatment (Figure 1(e)). L-dopa signiﬁcantly
reduced haloperidol-induced catalepsy (F(5, 50) = 7.13,
P<0.01) at 100mg/kg, whereas 300mg/kg approached
signiﬁcance (P = 0.06) compared to vehicle + haloperidol
treatment (Figure 1(f)).
3.2. Rat PPI. Figure 2 (left graphs) shows treatment eﬀects
on rat PPI, and Table 1 shows treatment eﬀects on rat startle
magnitude. The A2A antagonists SCH 412348 (Figure 2(a))
and istradefylline (Figure 2(b)) did not impair rat PPI (SCH
412348: F(3, 28) = 0.57, P>0.05; istradefylline: F(3, 28) =
1.18, P>0.05) orstartle magnitude (SCH 412348: F(3, 28) =
0.31,P>0.05;istradefylline:F(3,28) =0.20,P>0.05)atany
doses tested. Pramipexole (Figure 2(c)) signiﬁcantly reduced
PPI at all doses tested (0.3, 1, and 3mg/kg) (F(3, 60) = 4.47,
P<0.01) but also signiﬁcantly reduced startle magnitude
at all doses tested (F(3, 60) = 5.24, P<0.01) compared to
vehicle, which is consistent with previous ﬁndings [11]. Per-
golide (Figure 2(d)) impaired PPI at 0.3 and 3mg/kg (F(3,
60) = 5.64, P<0.01) but did not aﬀect startle (F(3, 60) =
1.29, P>0.05). Ropinirole (Figure 2(e)) did not impair PPI
in rats (F(4, 32) = 1.16, P>0.05) but reduced startle mag-
nitude at 3 and 30mg/kg (F(4, 32) = 4.61, P<0.01). For
L-dopa (Figure 2(f)), a one-way ANOVA revealed only a
marginally signiﬁcant eﬀect on PPI overall (F(4, 35) = 2.46,
P = 0.06). The two highest doses of L-dopa (100 and
300mg/kg)signiﬁcantlydisruptedPPI.Startlewasnotaﬀect-
ed by treatment with L-dopa (F(4, 35) = 0.23, P>0.05).
Apomorphine (Figure 2(g)) signiﬁcantly reduced PPI in rats
(F(4, 75) = 5.58, P<0.01) at all doses tested (0.3, 0.5, 0.65,
and 0.8mg/kg) but had no eﬀect on startle (F(4, 75) = 0.76,
P>0.05).
3.3. Mouse PPI. Figure 2 (right graphs) shows treatment
eﬀects on mouse PPI, and Table 2 shows treatment eﬀects on
mouse startle magnitude. SCH 412348 (Figure 2(a)) did not
signiﬁcantly decrease PPI or startle in mice (PPI: F(3, 36) =
0.74, P>0.05; startle: F(3, 36) = 0.14, P>0.05). Istra-
defylline (Figure 2(b)) approached overall signiﬁcance in re-
ducing mouse PPI (F(3, 36) = 2.83, P = 0.05). Istradefylline
(1mg/kg) signiﬁcantly reduced PPI compared to vehicle.
Startle was not aﬀected by istradefylline at any dose (F(3, 36)
= 1.26, P>0.05). Pramipexole (Figure 2(c)) signiﬁcantly re-
duced PPI in mice only at 1.0mg/kg (F(3, 44) = 2.91, P<
0.05).Unlikeitseﬀectsonratstartlemagnitude,pramipexole
did not signiﬁcantly reduce mouse startle (F(3, 44) = 2.53,
P>0.05). Pergolide (Figure 2(d)) signiﬁcantly reduced
mouse PPI and startle at 3mg/kg (PPI: F(4, 43) = 3.40,
P<0.05; startle: F(4, 43) = 3.63, P<0.05). Ropinirole
(Figure 2(e)) did not signiﬁcantly reduce mouse PPI (F(3,
36) = 2.09, P>0.05) or startle magnitude (F(3, 36) = 0.05,
P>0.05) at any dose tested. For L-dopa (Figure 2(f)), there
wasnosigniﬁcantmaineﬀectofdoseonPPI(F(4,42)=1.01,4 Parkinson’s Disease
Table 1: Mean startle magnitude ± SEM in rat prepulse inhibition
(∗P<0.05 versus vehicle).
Drug Dose (mg/kg) Startle
SCH 412348
Veh. 193.3 ± 46.6
0.3 223.4 ± 59.5
1.0 166.0 ± 20.2
3.0 213.0 ± 46.3
Istradefylline
Veh. 196.5 ± 50.8
0.1 163.7 ± 26.7
0.3 161.5 ± 23.3
1.0 175.0 ± 36.9
Pramipexole
Veh. 229.5 ± 32.1
0.3 121.4 ± 14.4∗
1.0 134.7 ± 32.0∗
3.0 101.6 ± 14.2∗
Pergolide
Veh. 139.9 ± 20.7
0.3 104.9 ± 27.1
1.0 111.0 ± 19.1
3.0 84.0 ± 11.1
Ropinirole
Veh. 250.2 ± 49.7
1.0 218.8 ± 33.7
3.0 73.0 ± 17.6∗
10.0 166.6 ± 26.7
30.0 111.4 ± 22.1∗
L-dopa
Veh. 228.7 ± 124.7
10 183.5 ± 31.0
30 269.8 ± 63.7
100 239.0 ± 45.1
300 197.2 ± 49.8
Apomorphine
Veh. 303.2 ± 46.3
0.3 323.5 ± 44.3
0.5 456.3 ± 140.0
0.65 468.1 ± 76.2
0.8 355.2 ± 79.6
P>0.05). However, startle was signiﬁcantly reduced by 100
and 300mg/kg of L-dopa (F(4, 42) = 5.48, P<0.01). Apo-
morphine (Figure 2(g)) signiﬁcantly reduced mouse PPI at
all doses tested (0.3, 1, and 3mg/kg) (F(3, 43) = 5.96, P<
0.01) but did not aﬀect startle magnitude (F(3, 43) = 2.58,
P>0.05).
4. Discussion
A2A receptor antagonism has received considerable recent
attentionasanalternativetreatmentforthemotorsymptoms
of PD [18, 19]. A2A receptor antagonists have proven to be
eﬃcacious in animal models of PD and in clinical studies.
Because they represent a nondopaminergic approach to the
treatment of PD, we hypothesized that A2A receptor antago-
nists will avoid neuropsychiatric side eﬀects associated with
dopaminergic therapies, including psychosis. The ﬁndings of
the present studies are consistent with this hypotheisis.
Table 2: Mean startle magnitude ± SEM in mouse prepulse inhi-
bition (∗P<0.05 versus vehicle).
Drug Dose (mg/kg) Startle
SCH 412348
Veh. 129.0 ± 17.8
0.3 144.6 ± 17.8
1.0 140.5 ± 20.7
3.0 142.6 ± 12.9
Istradefylline
Veh. 125.9 ± 22.3
0.1 104.9 ± 17.3
0.3 110.9 ± 19.0
1.0 75.9 ± 10.7
Pramipexole
Veh. 95.6 ± 8.7
0.3 103.1 ± 13.2
1.0 76.3 ± 8.5
3.0 69.5 ± 10.5
Pergolide
Veh. 135.2 ± 23.5
0.1 149.9 ± 12.3
0.3 116.9 ± 17.6
1.0 100.5 ± 15.1
3.0 62.7 ± 10.9∗
Ropinirole
Veh. 135.9 ± 19.7
3.0 134.1 ± 15.2
10.0 143.3 ± 15.6
30.0 140.6 ± 18.0
L-dopa
Veh. 130.5 ± 20.9
10.0 135.0 ± 16.4
30.0 96.8 ± 14.4
100.0 69.0 ± 5.8∗
300.0 50.7 ± 9.6∗
Apomorphine
Veh. 149.9 ± 26.4
0.3 93.1 ± 15.9
1.0 90.6 ± 15.2
3.0 94.7 ± 13.5
PPI can be measured in humans, rats, mice, and other
mammals and is deﬁcient in pathological or drug-induced
psychotic states. In the current studies, pramipexole, pergo-
lide, and apomorphine disrupted PPI in both rat and mouse.
Theseresultsareconsistentwithpreviousﬁndingsinrats[10,
11, 20]. Moreover, the disruptive eﬀects occurred at doses
that were eﬃcacious in rat haloperidol-induced catalepsy, a
rodent model of PD. Although Swerdlow et al. [10]f o u n d
thatzropinirole(3–6mg/kg)induceddeﬁcitsinratPPI,ropi-
nirole did not impair PPI in the present studies, even when
tested up to 30mg/kg in the rat and mouse. The diﬀerent
eﬀects on PPI between ropinirole and other DA receptor
agonistsareconsistentwiththeirclinicalproﬁles.PDpatients
treated with pramipexole have a signiﬁcantly higher risk of
experiencing hallucinations than patients treated with ropi-
nirole[21].Inaddition,ropiniroleislesslikelytoinducepsy-
chosis when used as monotherapy for PD than when admin-
istered adjunctively with other DA receptor agonists [22].
Likepramipexoleandpergolide,ropiniroleisapotentD2 and
D3 receptor agonist that favors the D3 receptor, as does theParkinson’s Disease 5
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Figure 1: Eﬃcacy of SCH 412348 (a), istradefylline (b), pramipexole (c), pergolide (d), ropinirole (e), and L-dopa (f) to reduce catalepsy
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tests (∗P<0.05; ∗∗P<0.01 versus vehicle + haloperidol treatment).6 Parkinson’s Disease
Veh 0.3 1 3
0
20
40
60
80
Veh 0.3 1 3
0
20
40
60
80
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
SCH 412348 (mg/kg)
Mouse
SCH 412348 (mg/kg)
Rat
(a)
Veh 0.1 0.3 1
0
20
40
60
80
Veh 0.1 0.3 1
0
20
40
60
80
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
∗
Istradefylline (mg/kg) Istradefylline (mg/kg)
(b)
Veh 0.3 1 3
0
20
40
60
80
Veh 0.3 1 3
0
20
40
60
80
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
∗ ∗ ∗
∗∗
Pramipexole (mg/kg) Pramipexole (mg/kg)
(c)
Veh 0.3 1 3
0
20
40
60
80
Veh 0.1 0.3 1 3
0
20
40
60
80
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
P
r
e
p
u
l
s
e
 
i
n
h
i
b
i
t
i
o
n
 
(
%
)
∗ ∗
∗∗
Pergolide (mg/kg) Pergolide (mg/kg)
(d)
Figure 2: Continued.Parkinson’s Disease 7
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Figure 2: Eﬀects of SCH 412348 (a), istradefylline (b), pramipexole (c), pergolide (d), ropinirole (e), L-dopa (f), and apomorphine (g) on
rat (left) or mouse (right) prepulse inhibition. Data represent mean % PPI ± SEM and were analyzed by one-way ANOVAs with Dunnett’s
tests (∗P<0.05; ∗∗P<0.01 versus vehicle treatment).
major metabolite of ropinirole [23]. As such, the diﬀerence
between ropinirole’s psychosis liability as compared to other
DA receptor agonists is not clearly understood.
WefoundthatL-dopaproducedamarginaldisruptionof
rat PPI but did not disrupt mouse PPI. There are conﬂicting
reports about the relative psychosis liability of L-dopa versus
DAreceptoragonists.SomeﬁndingsindicatethatL-dopahas
similar potential to DA receptor agonists to elicit psychosis
[24],whereasotherstudiessuggestthatDAagonistsaremore
likely to induce psychosis than L-dopa [5–7].
The clear lack of PPI disruption with SCH 412348 is
interesting considering that the eﬃcacy of both DA receptor
agonists and A2A antagonists is hypothesized to be mediated
bysimilareﬀectsatthesecondmessengerlevel.Thereceptors8 Parkinson’s Disease
are colocalized on neurons in the striatopallidal indirect
pathwayofthebasalganglia.A2A receptorantagonistsandD2
receptor agonists decrease intracellular adenylyl cyclase acti-
vation[25].Thesepharmacologicalapproachesevokesimilar
behavioral proﬁles in rodents and primates. Several ﬁndings
provide evidence for extrastriatal DA receptor involvement
in PPI [26]. It is possible, therefore, that neuropsychiatric
side eﬀects associated with DA receptor agonists are, at least
partially, mediated by activity outside the striatum. Unlike
D2 receptors, A2A receptors are predominantly localized in
the striatum [14], which could explain their benign neuro-
psychiatric side eﬀect proﬁle.
Thedistinctionbetweenthetwoapproachesmaybeattri-
buted to diﬀerent eﬀects on the various DA receptor sub-
types. While it is well established that there is a functional
A2A-D2 receptor interaction, the relationship between A2A
and D3 r e c e p t o r si sl e s sw e l lu n d e r s t o o d[ 27]. Chang et al.
[20] demonstrated that PPI using acoustic startle is highly
sensitive to activation of the D3 receptor. More research is
necessarytobetterunderstandthepharmacologyresponsible
forthePPI-disruptiveeﬀectsofagonismatvariousDArecep-
t o rs u b t y p e sa sw e l la st h ed i ﬀerence between selective A2A
antagonists and DA receptor agonists reported herein.
Interestingly, istradefylline induced a marginal disrup-
tion of mouse PPI at the highest dose tested (1mg/kg). The
dissimilar eﬀects of SCH 412348 and istradefylline in rodent
PPI may be due to their relative activity at the adenosine A1
receptor. Whereas SCH 412348 is greater than 1000-fold
selective for the A2A receptor over the A1 receptor, istrade-
fylline exhibits only 82-fold selectivity [17]. Koch and
Hauber [28] found that the nonselective adenosine receptor
antagonist, theophylline, potentiated an apomorphine dis-
ruption of PPI. This eﬀect was reversed by a selective A1
receptor agonist but not a selective A2A receptor agonist.
Collectively, these data suggest that istradefylline’s activity at
the A1 receptor may have contributed to the disruption of
PPI observed at the highest dose tested.
Although psychotic symptoms may also occur in PD
patients in the absence of pharmacological treatment, it is
stilluncertainifthepathologyofthediseaseitselfpredisposes
the patients to developing neuropsychiatric symptoms with
dopaminergic treatment. Studies have suggested that PD-
associated psychosis results from interactions between phar-
macological and disease-related factors [29]. Considering
that the present studies were performed using healthy
animals, future PPI studies using an animal model of PD,
such as the MitoPark mouse, which has a gradual degen-
eration of dopamine cells and a parkinsonian phenotype
[30], may help elucidate the contribution of the disease
to the neuropsychiatric eﬀects of dopaminergic treatment.
Marcellino et al. [31] reported that chronic treatment with
an A2A antagonist alleviated the motor deﬁcits of MitoPark
mice. Therefore, a comparison of the eﬀects of A2A receptor
antagonists to dopamine receptor agonists in the sensory
gatingPPImodelusingMitoParkmicewouldbebeneﬁcialin
further understanding the potential beneﬁts of A2A receptor
antagonism as a treatment for PD without increased risk of
developing psychosis.
5. Conclusions
The highly selective A2A receptor antagonist, SCH 412348,
did not induce a PPI deﬁcit in either the rat or mouse. Con-
versely, DA receptor agonists used for the treatment of PD
demonstrated disruptive eﬀects in PPI. Istradefylline mod-
estly disrupted rodent PPI, which we attribute to its activity
at the adenosine A1 receptor. Clearly, more work is required
to understand the pharmacology of the disruptive eﬀects of
diﬀerentantiparkinsonianagents.Collectively,ourdataindi-
cate that A2A receptor antagonism is a promising nondop-
aminergic treatment for PD that may avoid neuropsychiatric
side eﬀects provided that the antagonist has suﬃcient selec-
tivity over the A1 receptor.
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